Source:http://linkedlifedata.com/resource/pubmed/id/11689556
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2002-1-4
|
pubmed:abstractText |
A series of potent and selective inducible nitric-oxide synthase (iNOS) inhibitors was shown to prevent iNOS dimerization in cells and inhibit iNOS in vivo. These inhibitors are now shown to block dimerization of purified human iNOS monomers. A 3H-labeled inhibitor bound to full-length human iNOS monomer with apparent Kd approximately 1.8 nm and had a slow off rate, 1.2 x 10(-4) x s(-1). Inhibitors also bound with high affinity to both murine full-length and murine oxygenase domain iNOS monomers. Spectroscopy and competition binding with imidazole confirmed an inhibitor-heme interaction. Inhibitor affinity in the binding assay (apparent Kd values from 330 pm to 27 nm) correlated with potency in a cell-based iNOS assay (IC50 values from 290 pm to 270 nm). Inhibitor potency in cells was not prevented by medium supplementation with l-arginine or sepiapterin, but inhibition decreased with time of addition after cytokine stimulation. The results are consistent with a mechanism whereby inhibitors bind to a heme-containing iNOS monomer species to form an inactive iNOS monomer-heme-inhibitor complex in a pterin- and l-arginine-independent manner. The selectivity for inhibiting dimerization of iNOS versus endothelial and neuronal NOS suggests that the energetics and kinetics of monomer-dimer equilibria are substantially different for the mammalian NOS isoforms. These inhibitors provide new research tools to explore these processes.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Nitric Oxide Synthase,
http://linkedlifedata.com/resource/pubmed/chemical/Nitric Oxide Synthase Type II,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0021-9258
|
pubmed:author |
pubmed-author:AuldDouglas SDS,
pubmed-author:BlaskoEricE,
pubmed-author:DevlinJames JJJ,
pubmed-author:FeldmanRichard IRI,
pubmed-author:GhoshSanjayS,
pubmed-author:GlaserCharles BCB,
pubmed-author:McMillanKirkK,
pubmed-author:ParkinsonJohn FJF,
pubmed-author:PhillipsGary BGB,
pubmed-author:PolokoffMark AMA,
pubmed-author:RamS BSB,
pubmed-author:StuehrDennis JDJ,
pubmed-author:WhitlowMarcM
|
pubmed:issnType |
Print
|
pubmed:day |
4
|
pubmed:volume |
277
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
295-302
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:11689556-Dimerization,
pubmed-meshheading:11689556-Enzyme Inhibitors,
pubmed-meshheading:11689556-Imidazoles,
pubmed-meshheading:11689556-Nitric Oxide Synthase,
pubmed-meshheading:11689556-Nitric Oxide Synthase Type II,
pubmed-meshheading:11689556-Pyrimidines,
pubmed-meshheading:11689556-Radioligand Assay
|
pubmed:year |
2002
|
pubmed:articleTitle |
Mechanistic studies with potent and selective inducible nitric-oxide synthase dimerization inhibitors.
|
pubmed:affiliation |
Cardiovascular Research, Berlex Biosciences, Richmond, California 94804-0099, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|